Open AccessComparison of efficacy and pharmacoeconomics of two helicobacter pylori eradication regimens in peptic ulcer disease
Author(s) -
Syeda Zaineb Kubra Hussaini,
Syeda Zaineb Humaira Hussaini,
Ruheena Yasmeen,
Bader Unnisa,
Aamir Ali Syed,
Naeem Khan,
Syed Ibrahim Hassan
Publication year - 2018
Publication title -
perspectives in clinical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 8
eISSN - 2229-5488
pISSN - 2229-3485
DOI - 10.4103/picr.picr_99_16
Subject(s) - pharmacoeconomics , helicobacter pylori , peptic ulcer , medicine , gastroenterology , disease , intensive care medicine
Helicobacter pylori , the cause of most peptic ulcer diseases, infects approximately 50% of the population worldwide. Indian data on cost and effectiveness of the standard first-line therapies for H. pylori eradication are scarce. Thus, the present study was aimed at comparing the cost and efficacy of two standard first-line therapies: Regimen I comprising pantoprazole (40 mg) plus amoxicillin (750 mg) plus clarithromycin (500 mg) (PAC) and Regimen II comprising rabeprazole (20 mg) plus amoxicillin (625 mg) plus metronidazole (200 mg) (RAM).